Fabry Disease Research Highlights
This 30-minute CME-accredited program highlights the latest clinical research about Fabry disease, a rare X-linked lysosomal disorder that results in the cellular buildup of globotriaosylceramide. Characteristic features of Fabry disease include acroparesthesias, angiokeratomas, hypohidrosis, corneal opacity, gastrointestinal problems, tinnitus, and hearing loss. Fabry disease also involves potentially life-threatening complications such as progressive kidney damage, heart attack, and stroke.
... |
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
Building and Maintaining a Multidisciplinary Team for Lysosomal Disorders
This CME/CE activity with Drs. Ozlem Goker-Aplan and Walla Al-Hertani describes the importance of a multidisciplinary team approach to managing lysosomal diseases, as well as some of the challenges involved in creating and maintaining that team.
At the end of this activity, participants should be able to:
- Describe the need for a team approach to care
- Describe best practices to build a multidisciplinary team for a new patient
- Describe best practices to maintain a multidisciplinary... |
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
Managing Cardiomyopathies in Lysosomal Disorders
This CME/CE activity describes the pathophysiologies and management options for lysosomal disease patients with cardiomyopathies.
At the end of this activity, participants should be able to:
- Describe the role of the cardiologist in the team approach to care
- Describe best practices to monitor cardiac symptoms in lysosomal disorders
- Describe best practices to treat cardiac symptoms in lysosomal disorders |
|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
Assessing, Monitoring, and Managing Respiratory Involvement in Lysosomal Disorders
Ozlem Gore-Alpan, MD of LDRTC and John Bach, MD, Professor of Neurology at Rutgers School of Medicine discuss best practices to manage respiratory complications in persons with lysosomal disorders.
At the end of this activity, participants should be able to:
- Describe the most common LSDs that have pulmonary complications.
- Describe best practices to manage pulmonary symptoms in Pompe disease.
- Describe best practices to manage pulmonary symptoms in MPSs.
- Describe best practices to... |
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the... |
|
|
Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) through mechanisms associated with increased atherogenesis, inflammation, and throm... |
|
Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases (ASCVD) through mechanisms associated with increased atherogenesis, inflammation, and thro... |
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
9th Annual Clinical Issues in Primary Care Conference
Presented by Continuing Education Company for over 30 years, our Primary Care CME Conference Series is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us in May 2024 for our 9th Annual Clinical Issues in Primary Care Conference at the Fairmont Orchid, Hawaii Resort on the Big Island
Program Objectives
As a result of this conference, participants will be able to:
Assess and p... |
|
Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood
Target Audience
The intended audience for this activity are neurologists, neuromuscular specialists, pediatric neurologists, genetic counselors, and pediatricians.
Program Overview
Join a panel of expert clinicians to identify the subtle and very early signs of DMD that may be detected before functional symptoms are noticed and that can help earlier diagnoses and appropriate interventions. Panelists will review the importance of matching mutations to therapeutic decisions, discuss emergin... |
|
Parkinson’s Disease " Updates in Diagnosis and Patient Management
Parkinson's disease is a neurodegenerative disorder, second only in prevalence to Alzheimer’s disease. Numerous therapeutic options, including carbidopa/levodopa, monoamine oxidase-B inhibitors, dopamine agonists, and device-assisted therapies, are available for treatment. These treatments are indicated at different stages following diagnosis. However, Parkinson’s disease progresses at highly variable rates, and no biomarkers, laboratory tests, or gold standard indexes are available t... |
|
Hot Topics in Lupus: SLE Pathophysiology
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
Hot Topics in Lupus: Individualizing Steroid-Sparing Regimens
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
Hot Topics in Lupus: Targeted Biologic Treatment Options
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
Case Challenges in nAMD and DME Management: Achieving Durable Response
The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni... |
|
Meeting Milestones in nAMD and DME Management: What's New?
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav... |
|
Graft vs Host Disease: Novel Management Strategies for a Chronic Condition
Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD.
Program Overview
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and invest... |
|
Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes
Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by ... |
|
In Case You Missed: Utilizing the Muscarinic System to Optimize Treatment Options for Schizophrenia
Schizophrenia is an incurable, neuropsychiatric disease characterized by difficulties thinking and communicating clearly as well as psychosis (ie, “positive” symptoms); difficulty functioning socially (ie, “negative” symptoms); and cognitive impairment. As many as 34% of patients with schizophrenia have treatment-resistant schizophrenia, defined as continuing symptoms despite at least 2 trials of appropriate antipsychotic treatment, and most people do not recover from it. Patients with... |
|
Managing Thyroid Eye Disease: Rapid Response From ENDO
For a timely diagnosis and optimal management of thyroid eye disease (TED), a multidisciplinary team of endocrinologists, ophthalmologists, oculoplastic surgeons, as well as other healthcare professionals is essential. Early diagnosis of TED through imaging and clinical assessment is imperative to allow for the timely initiation of therapeutic strategies that limit disfiguration and reduce the potential for vision loss. The recent updates to guidelines for the management of TED, along with the... |
|
32nd Annual Primary Care Conference, Session 1
Continuing Education Company has been organizing its Primary Care Conference Series for over 31 years. The Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this June or July when we hold the 32nd Annual Primary Care Conference. This conference will be repeated in two sessions for convenience in scheduling. Sessions I and II will be held at the Kiawah Is... |
|
Major Depressive Disorder & Postpartum Depression: Targeting the GABA Deficit
Major depressive disorder (MDD), perinatal depression, and postpartum depression (PPD) are increasingly prevalent conditions that carry an extremely high disease burden. Underdiagnosis and undertreatment of major depressive episodes have led to significant unmet needs for these patient populations. Success of treatment with traditional antidepressants that target monoaminergic deficiencies and imbalances is limited by non- or incomplete therapeutic response as well as delayed onset of action. ... |
|
Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a... |
|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
Gastroenterology 2024 - LIVE STREAMING
The Comprehensive 2024 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2024 program include:
• Updated... |
|
Internal Medicine Comprehensive Review and Update 2024 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 64th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine
... |
|
32nd Annual Primary Care Conference, Session 2
Continuing Education Company has been organizing its Primary Care Conference Series for over 31 years. The Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this June or July when we hold the 32nd Annual Primary Care Conference. This conference will be repeated in two sessions for convenience in scheduling. Sessions I and II will be held at the Kiawah Is... |
|
Neuromyelitis Optica Spectrum Disorder: Updates on Diagnosis and Treatment Management
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. Unfortunately, early stages of NMOSD are frequently misdiagnosed as multiple sclerosis or other diseases. Diagnosis is typically based on the presence of key clinical characteristics"aquaporin-4 (AQP4) antibody status and magnetic resonance imaging. The application of newer diagnostic criteria may as... |
|
15th Annual Essentials in Primary Care Summer Conference
Continuing Education Company has been organizing its Primary Care Conference Series for over 30 years. The Essentials in Primary Care Summer Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this July when we hold the 15th Annual Essentials in Primary Care Summer Conference.
This conference will be held at the Hammock Beach Resort in Palm Coast, Florida. Located n... |
|
Reducing Risks in Asthma: Mucus Plugs and Airway Obstruction
Target Audience
The educational design of this activity addresses the needs of pulmonology and clinical immunology clinicians who manage patients with severe asthma who are at risk for mucus plugs.
Program Overview
This Point-of-Care 201 program has been designed to educate and promote critical thinking through a discussion-based format that is accompanied by 3-dimensional animation. Expert faculty examine various sides of key clinical issues in asthma"including exploration of the pa... |
|
Developing Optimal Strategies for Reducing Morbidity in Patients with Non-Cystic Fibrosis Bronchiectasis
This case-based morbidity and mortality review (MMR) assesses the negative implications of suboptimal therapeutic management for patients with non-cystic fibrosis bronchiectasis. Cases and expert discussion focus on ensuring a prompt and accurate diagnosis of bronchiectasis, understanding the benefits of high frequency chest wall oscillation (HFCWO), and identifying patients who can benefit from HFCWO. |
|
Answers to the Questions You May Not be Asking: Treating Ulcerative Colitis Considerate of Patient-Centric Factors
Are you aware of the latest evidence-based strategies in ulcerative colitis (UC)? Looking to expand your ability to incorporate patient-centric factors into selection of therapy for UC? Navigate through this novel, interactive self-directed activity designed to optimize your decision making in selection of therapy for UC. View expert perspectives and insights who can help you apply newer strategies such as treat-to-target (T2T) and therapeutic drug monitoring (TDM) for the treatment for your ... |
|
The Importance of Early Recognition of Tay-Sachs and Sandhoff Disease
Faculty experts Jeanine Jarnes, PharmD, and Chester Whitley, MD, PhD, delve into the rare and difficult to diagnose GM2-gangliosidoses Tays-Sachs and Sandhoff diseases. Following a discussion of the etiology and pathophysiology of these diseases, the faculty use real-life cases to illustrate the various phenotypes of these conditions, as well as key presenting signs and symptoms. Diagnostic approaches are discussed, alongside current standards of care, including supportive and palliative treat... |
|
Assessment of Asthma Control
Although asthma treatments are widely available, between one-third and one-half of patients continue to have symptoms that regularly interfere with everyday life. These asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year, which often lead to inpatient hospital stays. Thus, there is a clear need for ongoing education about asthma management, particularly when there are significant changes in treatment recommendations or therapeutic options.... |
|
8th Annual Internal Medicine in Primary Care Conference
Continuing Education Company has been organizing its Primary Care Conference Series for over 30 years. The 8th Annual Internal Medicine in Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us July 26 through August 2, 2024 when we host the 8th Annual Internal Medicine in Primary Care Conference on the Celebrity Edge while cruising Alaska and British Columbi... |
|
AxSpA Boot Camp: Are You Up to Date on Recent Advances?
With a multitude of possible clinical presentations and a lack of validated diagnostic criteria, late or missed diagnosis of AxSpA is all too common in clinical practice. Further complicating diagnosis, a subset of patients with AxSpA do not exhibit radiographic changes on plain film x-ray. With recent advances in the therapeutic armamentarium able to halt the irreversible structural changes associated with AxSpA progression, it is more important than ever to diagnose AxSpA as early as possibl... |
|
Diabetes Comorbidities and Complications - LIVE STREAMING
This comprehensive course, which is among the highest-rated Harvard Medical School CME courses, provides education and updates to optimize your care of patients with diabetes and these conditions:
• Obesity
• Cardiovascular Disease
• Heart Failure
• Coronary Artery Disease
• Cerebrovascular Disease
• Hypertension
• Hyperglycemia
• Hypoglycemia
• Dyslipidemia
• Metabolic-Associated Fatty Liver Disease
• Chronic Kidney Disease
Sessions are led by experts in thes... |
|
The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age-Related Macular Degeneration in an Era of Expanded Treatment Options; AMD Virtual Pathways Activity
Target Audience
This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties.
Program Overview
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological ... |
|
Rescue Therapies for Asthma
Although asthma treatments are widely available, between one-third and one-half of patients continue to have symptoms that regularly interfere with everyday life. These asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year, which often lead to inpatient hospital stays. Thus, there is a clear need for ongoing education about asthma management, particularly when there are significant changes in treatment recommendations or therapeutic options.... |
|
Best of ACTHIV® 2023: HIV 101: Pathogenesis
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2023 conference for the frontline HIV care team, this activity will describe HIV infection and viral dynamics, define how viral dynamics impact management of antiretroviral therapy, and describe current progress in area of HIV cure/remission.
Describe HIV infection and viral dynamics
Define how viral dynamics impact management of antiretroviral therapy.
Describe current progress in area of... |
|
Best of ACTHIV® 2023: Hepatitis B in People with HIV
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2023 conference for the frontline HIV care team, this module will examine best practices for evaluating people with HBV and HIV and will review the risk of liver complications associated with HBV viremia in people with HIV.
Describe best practices for evaluating people with HBV and HIV
Appraise the risk of liver complications associated with HBV viremia in people with HIV |
|
Best of ACTHIV® 2023: Diabetes Management and Weight Loss in People with HIV
Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2023 conference for the frontline HIV care team, this module discusses how to determine an appropriate diabetes medication regimen for patients with HIV and how to select an appropriate weight loss medication option for patients with HIV.
Determine an appropriate diabetes medication regimen for patients with HIV
Select an appropriate weight loss medication option for patients with HIV |